Covered recipient · General Payments record
ISAAC TAFUR
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$138.59
9 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $112.81 | 7 |
| Education | $25.78 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.19 | 2 |
| Seagen Inc. | $34.69 | 2 |
| Merck Sharp & Dohme Corporation | $19.08 | 1 |
| PFIZER INC. | $13.86 | 1 |
| Gilead Sciences, Inc. | $11.92 | 1 |
| Janssen Biotech, Inc. | $11.63 | 1 |
| AstraZeneca Pharmaceuticals LP | $11.22 | 1 |
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ISAAC TAFUR
NPI 1679536387 · CMS profile ID 30754
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
LUBBOCK, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679536387?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679536387?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679536387?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1679536387?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
9 matching records · $138.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–9 of 9.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.25 | 12/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813302541 | CMS |
| Seagen Inc. | $19.65 | 11/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832180095 | CMS |
| Seagen Inc. | $15.04 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832180051 | CMS |
| Janssen Biotech, Inc. | $11.63 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788551681 | CMS |
| Merck Sharp & Dohme Corporation | $19.08 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848362401 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.22 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830121373 | CMS |
| Gilead Sciences, Inc. | $11.92 | 06/01/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845879923 | CMS |
| Novartis Pharmaceuticals Corporation | $17.94 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813302537 | CMS |
| PFIZER INC. | $13.86 | 03/19/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833269853 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $24,700.00 | 2 |
| PY2024 | Principal investigator | $850.00 | 2 |
| PY2023 | Principal investigator | $16,152.90 | 11 |
| PY2022 | Principal investigator | $75,305.83 | 35 |
| PY2021 | Principal investigator | $57,088.81 | 68 |
| PY2020 | Principal investigator | $164,987.76 | 78 |
| PY2019 | Principal investigator | $218,143.35 | 88 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
78 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Seagen Inc. | $300.00 | 12/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454649 |
| Principal investigator 1 | Seagen Inc. | $6,415.41 | 12/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454653 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 12/10/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742900197 |
| Principal investigator 1 | Seagen Inc. | $79.31 | 11/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454645 |
| Principal investigator 1 | Seagen Inc. | $2,500.00 | 11/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454651 |
| Principal investigator 1 | Seagen Inc. | $480.00 | 11/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454673 |
| Principal investigator 1 | Seagen Inc. | $100.00 | 11/18/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454647 |
| Principal investigator 1 | Seagen Inc. | $18,034.89 | 10/23/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454671 |
| Principal investigator 1 | Seagen Inc. | $21,898.19 | 10/20/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454655 |
| Principal investigator 1 | Seagen Inc. | $961.28 | 10/14/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454675 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275191 |
| Principal investigator 1 | Incyte Corporation | $8,000.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275193 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275195 |
| Principal investigator 1 | Incyte Corporation | $945.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275197 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275199 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 09/17/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275201 |
| Principal investigator 1 | Seagen Inc. | $1,000.00 | 09/10/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454609 |
| Principal investigator 1 | Seagen Inc. | $15,098.19 | 08/26/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454623 |
| Principal investigator 1 | PFIZER INC. | $3,031.26 | 08/20/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742911285 |
| Principal investigator 1 | Seagen Inc. | $800.00 | 08/04/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454607 |
| Principal investigator 1 | Seagen Inc. | $35.96 | 08/04/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454627 |
| Principal investigator 1 | Seagen Inc. | $2,001.11 | 07/07/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454625 |
| Principal investigator 1 | Seagen Inc. | $2,500.00 | 07/07/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) | No dispute reported | 06/30/2026 | 733454629 |
| Principal investigator 1 | Seagen Inc. | $800.00 | 07/07/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) | No dispute reported | 06/30/2026 | 733454631 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 07/01/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742907321 |
| Principal investigator 1 | PFIZER INC. | $1,802.76 | 06/16/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742907711 |
| Principal investigator 1 | Seagen Inc. | $35.96 | 06/16/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454379 |
| Principal investigator 1 | Seagen Inc. | $2,500.00 | 06/09/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454377 |
| Principal investigator 1 | Seagen Inc. | $12,600.00 | 06/09/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) | No dispute reported | 06/30/2026 | 733454399 |
| Principal investigator 1 | Eli Lilly and Company | $5,687.85 | 06/02/2020 | Non-covered Recipient Entity METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 | No dispute reported | 06/30/2026 | 728738785 |
| Principal investigator 1 | Seagen Inc. | $750.00 | 06/02/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454375 |
| Principal investigator 1 | Seagen Inc. | $227.50 | 05/28/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454369 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 05/19/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742908497 |
| Principal investigator 1 | Seagen Inc. | $500.00 | 05/06/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454371 |
| Principal investigator 1 | Seagen Inc. | $2,643.52 | 05/06/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454373 |
| Principal investigator 1 | PFIZER INC. | $6,553.09 | 05/05/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742908737 |
| Principal investigator 1 | PFIZER INC. | $2,960.75 | 05/05/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742912353 |
| Principal investigator 1 | PFIZER INC. | $1,978.18 | 04/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742906591 |
| Principal investigator 1 | PFIZER INC. | $1,978.18 | 04/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742907039 |
| Principal investigator 1 | PFIZER INC. | $2,603.25 | 04/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742907175 |
| Principal investigator 1 | PFIZER INC. | $2,960.75 | 04/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742909921 |
| Principal investigator 1 | PFIZER INC. | $4,406.01 | 04/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742909991 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275115 |
| Principal investigator 1 | Incyte Corporation | $70.21 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275117 |
| Principal investigator 1 | Incyte Corporation | $35.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275119 |
| Principal investigator 1 | Incyte Corporation | $103.60 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275121 |
| Principal investigator 1 | Incyte Corporation | $30.09 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275123 |
| Principal investigator 1 | Incyte Corporation | $0.02 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275125 |
| Principal investigator 1 | Incyte Corporation | $0.10 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275127 |
| Principal investigator 1 | Incyte Corporation | $52.12 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275129 |
| Principal investigator 1 | Incyte Corporation | $15.40 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275131 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275141 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275143 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275145 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275147 |
| Principal investigator 1 | Incyte Corporation | $10.80 | 04/08/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | No dispute reported | 06/30/2026 | 744275149 |
| Principal investigator 1 | Incyte Corporation | $17.90 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275101 |
| Principal investigator 1 | Incyte Corporation | $35.80 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275103 |
| Principal investigator 1 | Incyte Corporation | $0.80 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275105 |
| Principal investigator 1 | Incyte Corporation | $53.70 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275107 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275109 |
| Principal investigator 1 | Incyte Corporation | $15.40 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275111 |
| Principal investigator 1 | Incyte Corporation | $52.12 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275113 |
| Principal investigator 1 | Incyte Corporation | $17.90 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275133 |
| Principal investigator 1 | Incyte Corporation | $17.90 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275135 |
| Principal investigator 1 | Incyte Corporation | $17.90 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275137 |
| Principal investigator 1 | Incyte Corporation | $35.80 | 04/02/2020 | Covered Recipient Teaching Hospital Covenant Health System | A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) | No dispute reported | 06/30/2026 | 744275139 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/24/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742911237 |
| Principal investigator 1 | Seagen Inc. | $500.00 | 03/11/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 733454363 |
| Principal investigator 1 | Eli Lilly and Company | $5,403.25 | 02/19/2020 | Non-covered Recipient Entity METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL | A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 728744777 |
| Principal investigator 1 | Exelixis Inc. | $202.80 | 02/06/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736575079 |
| Principal investigator 1 | Exelixis Inc. | $269.43 | 02/06/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736575081 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 02/04/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736575083 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 01/21/2020 | Covered Recipient Teaching Hospital COVENANT HEALTH SYSTEM | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 742906141 |
| Principal investigator 1 | Seagen Inc. | $316.62 | 01/21/2020 | Non-covered Recipient Entity JOE ARRINGTON CANCER CENTER | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 733454585 |
| Principal investigator 1 | Exelixis Inc. | $6,242.60 | 01/07/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736574605 |
| Principal investigator 1 | Exelixis Inc. | $240.50 | 01/07/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736574607 |
| Principal investigator 1 | Exelixis Inc. | $46.80 | 01/07/2020 | Non-covered Recipient Entity Methodist Children's Hospital dba Covenant Children's Hospital | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 736574609 |